Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation of Plasmodium falciparum
Antimicrobial Agents and Chemotherapy · 2025-10 · 69 (10)
DOI: 10.1128/aac.00471-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025-10. Verfasst von Vella Nikolova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Göttingen, Germany. Hauptthemen laut MEDLINE: Plasmodium falciparum, Pyrimethamine, Antimalarials. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Council.
Abstract (Originalsprache)
Malaria tropica, caused by Plasmodium falciparum ( P. falciparum ), remains a global health challenge with limited therapeutic options. In mammalian cells, the small-molecule compound RAS-selective lethal 3 (RSL3) induces ferroptosis via lipid peroxidation. In this study, we demonstrate that RSL3 synergizes with Pyrimethamine, an inhibitor of P. falciparum dihydrofolate reductase (DHFR), to suppress parasite proliferation in red blood cells (RBCs). A similar synergistic effect was observed with Cycloguanil, a structural analog of Pyrimethamine, but not with other DHFR inhibitors or alternative agents that induce ferroptosis in nucleated mammalian cells. Notably, Ferrostatin-1, an antagonist of lipid peroxidation, largely failed to rescue parasite growth in the presence of RSL3, possibly suggesting a mechanism distinct from canonical ferroptosis. These findings suggest that the synergy may involve unidentified targets of RSL3 and Pyrimethamine in P. falciparum , divergent from those described in mammalian systems. Moreover, RSL3 and related compounds could serve as promising adjuvants to enhance the antimalarial efficacy of Pyrimethamine and potentially overcome drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Göttingen, Germany.
- Center for Infectious Diseases - Parasitology, Medical Faculty, Heidelberg University, Heidelberg, Germany.
- Institute of Medical Microbiology and Virology, University Medical Center Göttingen, Göttingen, Germany.
- Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
ORCID-Profile: Vella Nikolova, Markus Ganter, Carsten G Lüder, Matthias Dobbelstein
Förderung
- German Research Council
Zitieren
APA
Nikolova, V., Linnemannstöns, K., Zahoruiko, A., Ganter, M., Lüder, C. G., & Dobbelstein, M. (2025). Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 69(10). https://doi.org/10.1128/aac.00471-25
Vancouver
Nikolova V, Linnemannstöns K, Zahoruiko A, Ganter M, Lüder CG, Dobbelstein M. Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation of Plasmodium falciparum. Antimicrobial Agents and Chemotherapy. 2025;69(10). doi:10.1128/aac.00471-25
BibTeX
@article{Nikolova2025,
author = {Nikolova, Vella and Linnemannstöns, Karen and Zahoruiko, Anastasiia and Ganter, Markus and Lüder, Carsten G and Dobbelstein, Matthias},
title = {Synergistic activity of RSL3 and Pyrimethamine to inhibit the proliferation of Plasmodium falciparum},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {10},
doi = {10.1128/aac.00471-25}
}
EUVIMED